PharmaNet Collaborates With the Cancer Immunotherapy Trials Network
PRINCETON, N.J., June 1, 2011 /PRNewswire/ — PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that it is collaborating with the Cancer Immunotherapy Trials Network (CITN), a premier network of clinical investigators, institutions and thought leaders in the area of cancer immunotherapy and vaccines, in order to help identify trials with immunotherapy agents prioritized by the CITN as having high potential for cancer therapy.
“We are thrilled to collaborate with the Cancer Immunotherapy Trials Network multi-investigator team,” commented Anthony Maida, PhD, MA, MBA, Vice President, Clinical Research and General Manager, Oncology. “The association allows us to identify oncology centers of excellence and thought leaders to collaborate on the development of cutting-edge therapeutics.”
PharmaNet has been conducting clinical studies for innovative oncology products since 1996 and has an experienced team, including on-staff oncologists, dedicated to the development of cancer treatments. The Company has extensive experience in the development of cytotoxic chemotherapies, monoclonal antibodies, pathway inhibitors and therapeutic vaccines in most solid tumor types. Two hundred local, regional and global oncology clinical trials have been awarded to PharmaNet in the past five years, including eleven registration programs, seven which resulted in NDA/MAA approvals.
PharmaNet’s focus on the development of immunotherapies and cancer vaccines is based on a core team of immunotherapy experts and partnerships to support this initiative.
“Clinical development of immunotherapies and cancer vaccines requires a special understanding of the mechanism of action and a different approach than traditional cancer therapies,” Dr. Maida added. “We are working with clients to address the unique methodologies needed to evaluate efficacy and safety of this class of innovative therapeutics.”
PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.
About Cancer Immunotherapy Trials Network (CITN)
The CITN is a multi-investigator team formed to bring new immunotherapy agents to the clinic, with an emphasis on clinical trials of “high priority” agents that were identified at the 2007 National Cancer Institute (NCI) immunotherapy agent workshop and on clinical trials using combination products. In 2010, the CITN was funded by the National Institute for Health through a $14 million grant to the Fred Hutchinson Cancer Research Center where Dr. Martin ‘Mac’ Cheever is a principle investigator. For more information, please visit http://monacoa.fhcrc.org/science/vidd/programs/citn/index.html.
Contact: Anne-Marie Hess Phone: (609) 951-6842 E-mail: email@example.com
SOURCE PharmaNet Development Group, Inc.